| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Harmon Seth | Chief Financial Officer | C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM | /s/Jennifer Tousignant, Attorney-in-fact | 04 Mar 2026 | 0001993300 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | VRDN | Common Stock | 1,711 | 03 Mar 2025 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | This amendment is being filed to correct the number of shares beneficially owned by the Reporting Person as reported in the original Form 4 filed with the Securities and Exchange Commission on March 4, 2025, which inadvertently omitted an aggregate of 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. |